Curza’s oncology program targets the most commonly diagnosed cancer—breast cancer—a disease that affects 1 in 6 women in their lifetime.
We have developed a powerful discovery platform for novel oncology therapeutics by combining new molecular scaffolds from Curza and the University of Utah with cutting edge disease models at the Huntsman Cancer Institute. Out of this platform, Curza has discovered a proprietary heterocyclic core that interferes with trace metal homeostasis and selectively promotes cell death in cancer cell lines. Curza’s lead program includes compounds that are efficacious in-vivo (tumor reduction and increased survival rate) and that are well tolerated. Compounds from this class would be the first to exploit a clinically absent method of action in the treatment of breast cancer.